Please try another search
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Paul Ginsburg | - | 2011 | Scientific Advisor of Intellectual Property |
Leo Ehrlich | 63 | 2007 | Chairman, CEO, CFO, Principal Accounting Officer & Secretary |
Stephen T. Sonis | - | 2016 | Scientific Advisor of Oral Mucositis & Member of the Advisory Board |
Francis A. Farraye | - | - | Scientific Advisor of Gastroenterology & Member of the Advisory Board |
William F. DeGrado | - | 2020 | Scientific Advisor of Drug Discovery & Clinical Development |
Gustavo H. Goldman | - | 2023 | Scientific Advisor of Mycology & Fungal Diseases and Member of the Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review